Illumina (ILMN) Stock Forecast, Price & News

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 3 sell ratings, 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.

17 equities research analysts have issued twelve-month price targets for Illumina's shares. Their ILMN share price forecasts range from $111.00 to $350.00. On average, they expect the company's share price to reach $229.80 in the next year. This suggests a possible upside of 73.0% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.

Illumina's stock was trading at $202.20 on January 1st, 2023. Since then, ILMN shares have decreased by 34.3% and is now trading at $132.86.
View the best growth stocks for 2023 here.

Illumina saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 5,950,000 shares, an increase of 5.5% from the August 31st total of 5,640,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the days-to-cover ratio is presently 3.8 days.
View Illumina's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ILMN earnings forecast.

Illumina, Inc. (NASDAQ:ILMN) released its earnings results on Wednesday, August, 9th. The life sciences company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.02 by $0.30. The life sciences company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.16 billion. Illumina had a positive trailing twelve-month return on equity of 1.97% and a negative net margin of 93.86%. The company's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.57 EPS.
Read the conference call transcript.

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), VanEck Biotech ETF (BBH), Global X Telemedicine & Digital Health ETF (EDOC), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Illumina updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of $0.75-$0.90 for the period, compared to the consensus EPS estimate of $1.31. The company issued revenue guidance of $4.63 billion-$4.63 billion, compared to the consensus revenue estimate of $4.91 billion.

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (8.84%), Geode Capital Management LLC (2.20%), Bank of New York Mellon Corp (2.17%), Alliancebernstein L.P. (1.98%), Northern Trust Corp (1.08%) and Veritas Asset Management LLP (0.96%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends.

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ILMN stock can currently be purchased for approximately $132.86.

Illumina (NASDAQ:ILMN) has a market capitalization of $21.03 billion and generates $4.58 billion in revenue each year. The life sciences company earns $-4,404,000,000.00 in net income (profit) each year or ($26.61) on an earnings per share basis.

The company employs 10,260 workers across the globe.

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.